Over the past three months, a group of 11 penny stocks has delivered standout returns, with gains starting at 30% — and three of them emerging as multibaggers. These high flyers were shortlisted based on a focused set of filters: a market capitalization below Rs 1,000 crore, a share price under Rs 20, and a…
Cipla Q1 FY26 Results: Mumbai-headquartered pharmaceutical firm Cipla on Friday reported a 10.2 per cent year-on-year rise in consolidated net profit to Rs 1,298 crore for the quarter ended June 30, beating analysts’ expectations. Cipla shares spiked immediately after the earnings announcement as the results were announced during the market hours, finishing the day 3.0 per…
Domestic equity benchmarks registered sharp losses on Friday, July 25, amid selling pressure across most sectors. Financial stocks took a major blow after Bajaj Finance posted a weak set of quarterly numbers. Investors weighed a newly signed trade pact with the UK that will lower duties on several items, including whisky and cars. Both headline…
Indian equity markets extended losses on Friday amid rising anxiety over the pending India-US trade deal, weak corporate earnings, and persistent foreign investor selling. Key indices dropped nearly 1 per cent, with most sectors and broader markets in the red. As of 2:53 PM IST, the BSE Sensex had declined 748.22 points (0.91 per cent)…
Cipla Q1 FY26 Results Preview: Mumbai-headquartered drug maker Cipla is set to report its financial results for the April-June period on Friday, July 25. Analysts expect the pharmaceuticals company to stage a mixed financial performance for the first three months of FY26, with a 10 per cent decline in the company’s US revenue. In FY25,…
Indian equity markets are likely to open on a weak note on Friday, weighed down by mixed global cues, weekly forex data, and a cautious stance ahead of a heavy earnings day. At 6:36 AM, GIFT Nifty futures were trading 121 points lower at 24,974, signaling a gap-down start for the benchmark indices. Key Factors…